Advaxia Biologics

Advanced analytical methods play a crucial role in ensuring the quality and safety of vaccines throughout their development. At Advaxia Biologics, we leverage these techniques to streamline the development and manufacturing of viral-based vaccines, improving product quality and operational efficiency. By optimizing our analytical processes, we enable smoother transitions from the bench to the clinic, ultimately accelerating the availability of safe and effective vaccines. 📅 If you’re interested in how advanced analytical methods are transforming vaccine production, join Esposito Nicola tomorrow, October 30th, at 14:55 in Theatre 1 at The World Vaccine Congress Europe in Barcelona. We also invite you to visit us at booth 46 to meet our team and explore our advancements in biopharmaceutical manufacturing. Patrick DePalma Stefania Di Marco Erik Noeldeke-Hollmann Meg Sweeney #WorldVaccineCongress #WVCEU #CDMO #Advaxia #Biologics

In the fast-paced world of complex biologics innovation, overcoming bottlenecks and quality issues in development and manufacturing can be daunting. But we're here to help. Advaxia Biologics specializes in tackling the toughest challenges when progressing transformative therapies from concept to the clinic. Our 𝗽𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗯𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝘀 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 translate intricate research & development into scalable, compliant drug products—ensuring you're ready for clinical trial supply. 🤝 Meet our team at 𝗕𝗼𝗼𝘁𝗵 𝟰𝟲 during the The World Vaccine Congress 𝗘𝘂𝗿𝗼𝗽𝗲 in Barcelona, and let’s discuss how we can simplify your path to success. 𝗥𝗲𝗮𝗱𝘆 𝘁𝗼 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗲? Stefania Di Marco Patrick DePalma Esposito Nicola Erik Noeldeke-Hollmann Meg Sweeney #WorldVaccineCongress #WVCEU #CDMO #Advaxia #Biologics

CPHI has been great so far, giving us the opportunity to connect with inspiring industry leaders and innovators. 👉𝗩𝗶𝘀𝗶𝘁 𝘂𝘀 𝗮𝘁 𝗦𝘁𝗮𝗻𝗱 𝟯𝗚𝟭𝟯𝟰 𝘁𝗼 𝗺𝗲𝗲𝘁 𝗼𝘂𝗿 𝘁𝗲𝗮𝗺 𝗮𝗻𝗱 𝗲𝘅𝗽𝗹𝗼𝗿𝗲 𝗽𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻. With over a decade of biologics experience, our fully integrated services — from expression systems to cGMP manufacturing — provide a seamless path from development to clinical supply. We look forward to discovering new opportunities to advance biologics innovation. #Advaxia #CDMO #CPHI2024 #CPHIworldwide

𝗣𝗮𝗿𝘁𝗻𝗲𝗿𝗶𝗻𝗴 𝗳𝗼𝗿 𝗽𝗿𝗼𝗴𝗿𝗲𝘀𝘀 𝗶𝗻 𝗯𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝘀 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁—𝗰𝗼𝗺𝗲 𝘀𝗲𝗲 𝘂𝘀 𝗮𝘁 CPHI 𝟮𝟬𝟮𝟰! Advaxia Biologics specializes in producing investigational 𝗯𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝘀, including 𝗮𝗱𝗲𝗻𝗼𝘃𝗶𝗿𝘂𝘀-𝗯𝗮𝘀𝗲𝗱 𝘃𝗮𝗰𝗰𝗶𝗻𝗲𝘀 and 𝗴𝗲𝗻𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀. We collaborate with transformative pharmaceutical companies worldwide, bringing innovative solutions to life while strictly adhering to cGMP standards, resulting in a 𝗳𝗹𝗮𝘄𝗹𝗲𝘀𝘀 𝘁𝗿𝗮𝗰𝗸 𝗿𝗲𝗰𝗼𝗿𝗱 𝗳𝗼𝗿 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗯𝗮𝘁𝗰𝗵𝗲𝘀. 📍 Visit us at 𝗦𝘁𝗮𝗻𝗱 𝟯𝗚𝟭𝟯𝟰 to discover how we can collaborate and drive your projects forward. 📅 Or schedule a meeting through the following link: https://lnkd.in/db-SqS8b Let’s connect and explore new opportunities together! #Advaxia #CDMO #CPHI2024 #CPHIworldwide

From cell line selection to final drug product fill, see how we ensure the highest standards of quality and precision in biologics production. Watch the full video and discover more about Advaxia Biologics’s advanced development & manufacturing solutions by visiting our capabilities page. 🎥 FULL VIDEO HERE: https://lnkd.in/dRCWKUVW #Capabilities #biologics #cdmo #gmpmanufacturing #Advaxia

𝐈𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐢𝐧𝐠 𝐨𝐮𝐫 𝐧𝐞𝐰 𝐬𝐭𝐚𝐭𝐞-𝐨𝐟-𝐭𝐡𝐞-𝐚𝐫𝐭 𝐪𝐮𝐚𝐥𝐢𝐭𝐲 𝐜𝐨𝐧𝐭𝐫𝐨𝐥 (𝐐𝐂) 𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐨𝐫𝐢𝐞𝐬 The pharmaceutical and biotech industries rely heavily on advanced analytical techniques to streamline drug development and manufacturing processes. Careful selection and optimization of analytical methods are crucial for 𝗤𝘂𝗮𝗹𝗶𝘁𝘆 𝗯𝘆 𝗗𝗲𝘀𝗶𝗴𝗻 (𝗤𝗯𝗗) product development, regulatory compliance, and overall efficiency. Advaxia Biologics exemplifies how the optimization of analytical methods can significantly enhance and accelerate drug development from preclinical to clinical phases. With our newly built and 𝗚𝗠𝗣-𝗰𝗲𝗿𝘁𝗶𝗳𝗶𝗲𝗱 𝗤𝗖 𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗼𝗿𝗶𝗲𝘀, designed to meet the highest standards of safety and efficiency, we’re able to offer a broad range of 𝗽𝗿𝗼𝗱𝘂𝗰𝘁-𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗚𝗠𝗣 𝗮𝘀𝘀𝗮𝘆𝘀 applicable to various viral vectors, biologics, and gene therapy products (testing for clinical studies and commercial batches) including: // Digital/Quantitative/Nested PCR methods // Restriction analysis // Western blot // Cellular assays (e.g., immunostaining methods and ELISA) // UPLC // Compendial methods (Container closure integrity, Dynamic light scattering, Mycoplasma detection by PCR, Endotoxin (LAL) testing, Osmolality measurement, Conductivity, TOC, pH, Bioburden) Additionally, we perform 𝗹𝗼𝗻𝗴-𝘁𝗲𝗿𝗺 𝗮𝗻𝗱 𝗮𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲𝗱/𝗶𝗻-𝘂𝘀𝗲 𝘀𝘁𝗮𝗯𝗶𝗹𝗶𝘁𝘆 studies according to ICH Q1A and Q5C. Our new QC facility (𝘀𝘄𝗶𝗽𝗲 𝗳𝗼𝗿 𝗯𝗲𝗵𝗶𝗻𝗱-𝘁𝗵𝗲-𝘀𝗰𝗲𝗻𝗲𝘀 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀) is equipped with the latest technology and meticulously planned to support your GMP testing as well as R&D needs. Get in touch to discover more. #biologics #genetherapy #gmp #cdmo #ADVAXIA

With the Bio convention coming to a close, the #Advaxia BD team would like to express their gratitude to the current clients and future collaborators for meeting with the team. Here's to a fruitful final day of #Bio2024 and wishing everyone safe travels back home. Thank you!

The Bio International Convention in San Diego is a month away, so if you are attending, reach out to our team to set a meeting. Visit the Advaxia events page (https://lnkd.in/gX4aupER) or follow the link below to the Bio Partnering portal. https://lnkd.in/gYvxpA3c #BIO2024 #ADVAXIA

𝗔𝗱𝘃𝗮𝘅𝗶𝗮 𝗔𝗰𝗵𝗶𝗲𝘃𝗲𝘀 𝗛𝗶𝗴𝗵 𝗘𝗰𝗼𝗩𝗮𝗱𝗶𝘀 𝗥𝗮𝘁𝗶𝗻𝗴: 𝗔 𝗦𝘁𝗲𝗽 𝗙𝗼𝗿𝘄𝗮𝗿𝗱 𝗶𝗻 𝘁𝗵𝗲 𝗼𝘂𝗿 𝗦𝘂𝘀𝘁𝗮𝗶𝗻𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗝𝗼𝘂𝗿𝗻𝗲𝘆 We are proud to share that we’ve been awarded an impressive 𝗘𝗰𝗼𝗩𝗮𝗱𝗶𝘀 𝗿𝗮𝘁𝗶𝗻𝗴, marking a significant milestone in our commitment to sustainability. This certification is a testament to @Advaxia's dedication to 𝗘𝗻𝘃𝗶𝗿𝗼𝗻𝗺𝗲𝗻𝘁𝗮𝗹, 𝗦𝗼𝗰𝗶𝗮𝗹, 𝗮𝗻𝗱 𝗚𝗼𝘃𝗲𝗿𝗻𝗮𝗻𝗰𝗲 (𝗘𝗦𝗚) 𝗲𝘅𝗰𝗲𝗹𝗹𝗲𝗻𝗰𝗲, an essential component of modern business practices, especially within the pharmaceutical and biotech industries where sustainable and ethical practices can greatly reduce environmental impact. Studies, including one from the Journal of Sustainable Finance & Investment, show that 𝗳𝗶𝗿𝗺𝘀 𝘄𝗶𝘁𝗵 𝘀𝘁𝗿𝗼𝗻𝗴 𝗲𝗻𝘃𝗶𝗿𝗼𝗻𝗺𝗲𝗻𝘁𝗮𝗹 𝗽𝗼𝗹𝗶𝗰𝗶𝗲𝘀 𝗰𝗮𝗻 𝗿𝗲𝗱𝘂𝗰𝗲 𝘁𝗵𝗲𝗶𝗿 𝗰𝗮𝗿𝗯𝗼𝗻 𝗲𝗺𝗶𝘀𝘀𝗶𝗼𝗻𝘀 𝗯𝘆 𝘂𝗽 𝘁𝗼 𝟱𝟴% 𝗺𝗼𝗿𝗲 than those without, underscoring the critical role of ESG standards in promoting ecological balance as we observe Earth Day. We look forward to continuing our efforts in enhancing our ESG impact and contributing positively to our community and the planet. #Advaxia #Sustainability #EarthDay #ESG #CDMO

𝗔𝗱𝘃𝗮𝘅𝗶𝗮 𝗔𝗰𝗵𝗶𝗲𝘃𝗲𝘀 𝗛𝗶𝗴𝗵 𝗘𝗰𝗼𝗩𝗮𝗱𝗶𝘀 𝗥𝗮𝘁𝗶𝗻𝗴: 𝗔 𝗦𝘁𝗲𝗽 𝗙𝗼𝗿𝘄𝗮𝗿𝗱 𝗶𝗻 𝘁𝗵𝗲 𝗼𝘂𝗿 𝗦𝘂𝘀𝘁𝗮𝗶𝗻𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗝𝗼𝘂𝗿𝗻𝗲𝘆 We are proud to share that we’ve been awarded an impressive 𝗘𝗰𝗼𝗩𝗮𝗱𝗶𝘀 𝗿𝗮𝘁𝗶𝗻𝗴, marking a significant milestone in our commitment to sustainability. This certification is a testament to @Advaxia's dedication to 𝗘𝗻𝘃𝗶𝗿𝗼𝗻𝗺𝗲𝗻𝘁𝗮𝗹, 𝗦𝗼𝗰𝗶𝗮𝗹, 𝗮𝗻𝗱 𝗚𝗼𝘃𝗲𝗿𝗻𝗮𝗻𝗰𝗲 (𝗘𝗦𝗚) 𝗲𝘅𝗰𝗲𝗹𝗹𝗲𝗻𝗰𝗲, an essential component of modern business practices, especially within the pharmaceutical and biotech industries where sustainable and ethical practices can greatly reduce environmental impact. Studies, including one from the Journal of Sustainable Finance & Investment, show that 𝗳𝗶𝗿𝗺𝘀 𝘄𝗶𝘁𝗵 𝘀𝘁𝗿𝗼𝗻𝗴 𝗲𝗻𝘃𝗶𝗿𝗼𝗻𝗺𝗲𝗻𝘁𝗮𝗹 𝗽𝗼𝗹𝗶𝗰𝗶𝗲𝘀 𝗰𝗮𝗻 𝗿𝗲𝗱𝘂𝗰𝗲 𝘁𝗵𝗲𝗶𝗿 𝗰𝗮𝗿𝗯𝗼𝗻 𝗲𝗺𝗶𝘀𝘀𝗶𝗼𝗻𝘀 𝗯𝘆 𝘂𝗽 𝘁𝗼 𝟱𝟴% 𝗺𝗼𝗿𝗲 than those without, underscoring the critical role of ESG standards in promoting ecological balance as we observe Earth Day. We look forward to continuing our efforts in enhancing our ESG impact and contributing positively to our community and the planet. #Advaxia #Sustainability #EarthDay #ESG #CDMO